αグルコシダーゼ阻害薬

出版社： フジメディカル出版
著者：
発行日： 2007-02-20
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784939048432
電子書籍版： 2007-02-20 （初版第1刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,650 円(税込)

購入する

商品紹介

近年のαグルコシダーゼ阻害薬の大規模試験では，食後高血糖の心血管イベント発症リスクに対する抑制効果など，その有用性が証明されています．本書は，αグルコシダーゼ阻害薬の種類・作用機序から，実際の使い方，相互作用・副作用・服薬指導までをわかりやすく解説したポケットガイドです．

目次

  • 表紙
  • 序
  • 執筆者一覧
  • 目次
  • I. 食後高血糖と心血管障害の発症進展
  • II. 糖尿病治療におけるαグルコシダーゼ阻害薬の位置づけ
  • III. αグルコシダーゼ阻害薬の種類と特徴
  • 1. 開発の経緯と作用機序
  • 2. 種類と特徴
  • IV. αグルコシダーゼ阻害薬の臨床効果
  • 1. 食後過血糖改善作用
  • 単独療法
  • 併用療法
  • 2. αグルコシダーゼ阻害薬の多面的作用
  • 3. 2型糖尿病の発症予防効果からみた有用性
  • 4. 心血管疾患予防からみた有用性
  • V. αグルコシダーゼ阻害薬の効果的な使い方
  • 1. 合併症例
  • 肥満
  • 高血圧
  • 高脂血症
  • メタボリックシンドローム
  • 心血管病既往例
  • 非アルコール性脂肪性肝炎(NASH)
  • 2. 実際の処方例
  • VI. 禁忌・慎重投与・相互作用
  • VII. 副作用と服薬指導の注意点
  • VIII. αグルコシダーゼ阻害薬の今後の展望
  • IX. 食後血糖に関する疫学研究
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 食後高血糖と心血管障害の発症進展

P.17 掲載の参考文献
1) Booth GL et al:Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people:a population-based retrospective cohort study. Lancet 368:29-36, 2006
PubMed
2) Haffner SM et al:Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
PubMed
3) Juutilainen A et al:Type2 diabetes as a "coronary heart disease equivalent" :an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28:2901-2907, 2005
 
4) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986, 1993
 
5) UKPDS-study-group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). UK Prospective Diabetes Study (UKPDS)Group. Lancet 352:837-853, 1998
PubMed
6) DECODE-study-group:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. Europeall Diabetes Epidemiology Group. Diabetes Epidemiology:Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354:617-621, 1999
 
7) Hanefeld M et al:Risk factors for myocardial infarction and death in newly detected NIDDM:the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
PubMed
8) Temelkova-Kurktschiev TS et al:Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23:1830-1834, 2000
PubMed
9) Nishikawa T et al:Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
PubMed
10) Azuma K et al:A new En face method is useful to quantitate endothelial damage in vivo. Biochem Biophys Res Commun 309:384-390, 2003
 
11) Otsuka A et al:Temporal hyperglycemia with hyperglycemic-induced hyperinsulinemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. Diabetologia 48:2667-2674, 2005
 
12) Quagliaro L et al:Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells:the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52:2795-2804, 2003
PubMed
13) Ceriello A et al:Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation:effects of short-and long-term simvastatin treatment. Circulation 106:1211-1218, 2002
 
14) Yamasaki Y et al:Asymptomatic hyperglycemia is associated with increased intimal plus medial thickness of carotid artery. Diabetologia 38:585-591, 1995
PubMed
15) Kawamori R:Asymptomatic hyperglycaemia and early atherosclerotic changes. Diabetes Res Clin Pract 40:S35-42, 1998
PubMed

II. 糖尿病治療におけるαグルコシダーゼ阻害薬の位置づけ

P.26 掲載の参考文献
1) The DECODE study group on behalf of the European Diabetes Epidemiology Group:Glucose tolerance and mortality:comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 354:617-621, 1999
 
2) Tominaga M et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose:The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
 
3) Takami K et al:Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes. Diabetes Care 25:658-662, 2002
 
4) Rosenbaum P et al:Improved glycemic control by acarbose therapy in hypertensive diabetic patients:effects on blood pressure and hormonal parameters. Braz J Med Biol Res 35:877-884, 2002
PubMed
5) Hanefeld M et al:Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
PubMed
6) Leiter LA et al:Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition. Am J Hypertens 18:121-128, 2005
PubMed
7) Willms B et al:Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas:a randomized, placebo-controlled study. Diabet Med 9:755-761, 1999
PubMed
8) Phillips P et al:Acarbose Improves Glycemic Control in Overweight Type 2 Diabetic Patients Insufficiently Treated With Metformin. Diabetes Care 26:269-273, 2003
PubMed
9) Rabasa-Lhoret R et al:Use of an α-glucosidase inhibitor to maintain glucose homoeostasis during postprandial exercise in intensively treated Type 1 diabetic subjects. Diabet Med 18:739-744, 2001
 

III. αグルコシダーゼ阻害薬の種類と特徴

P.31 掲載の参考文献
1) Puls W et al:lnfluence of an-amylase inhibitor(BAY d 7791) on blood glucose, serum insulin and NEFA in starch loading tests in rats, dogs and man. Diabetologia 9:97-101, 1973
 
2) Bo-Linn GW et al:Starch blockers-their effect on calorie absorption from a high-starch meal. N Engl J Med 307:1413-1416, 1982
PubMed
3) Schmidt DD et al:alpha-Glucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften 64:535-536, 1977
PubMed
4) Samulitis BK et al:Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine. Drugs Exp Clin Res 13:517-524, 1987
PubMed
5) Kameda Y et al:Valiolamine, a new alpha-glucosidase inhibiting aminocyclitol produced by Streptomyces hygroscopicus. J Antibiot(Tokyo) 37:1301-1307, 1984
PubMed
6) Chiasson JL et al:STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
 
P.38 掲載の参考文献
1) Horii S:Valiolamine and Its N-Substituted Derivatives, α-D-Glucosidase Inhibitors:From Validamycins to Voglibose(AO-128), an Antidiabetic Agent. 武田研究所報 52:1, 1993
 
2) 小高裕之:二糖類水解酵素阻害剤AO-128のラットにおける食後高血糖抑制作用. 日本栄養･食糧学会誌 45:27-31, 1992
Medical*Online
3) Samulitis BK et al:Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine. Drugs Exp Clin Res 13:517-524, 1987
PubMed
4) Krause HP et al:Pharmacokinetics and Metabolism of Glucosidase inhibitors. Handbook of Experimental Pharmacology. 119:541-544, 1996
 
5) Van de Laar FA et al:Alpha-glucosidase inhibitors for patients with type 2 diabetes. Results from a Cochrane systematic review and meta-analysis. Diabetes Care 28:154-163, 2005
PubMed
6) Van de Laar FA et al:Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 18:CD003639, 2005
 

IV. αグルコシダーゼ阻害薬の臨床効果

P.45 掲載の参考文献
1) 日本糖尿病学会編:科学的根拠に基づく糖尿病診療ガイドライン. 糖尿病 45(Suppl 1), 2002
 
2) The DECODE Study Group, the European Diabetes Epidemiology Group:Glucose tolerance and cardiovascular mortality:comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405, 2001
 
3) Tominaga M et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Tha Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
 
4) Chiasson JL et al:STOP-NIDDM Trial Research Group:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial. JAMA 290:486-494, 2003
 
5) Hara T et al:An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibitor in NIDDM. Diabetes Care 19:642-647, 1996
 
6) 羽根田隆ほか:ボグリボース口腔内崩壊錠(ベイスンOD錠) 導入後にみられた服薬コンプライアンスおよびHbA1cの改善. Progress in Medicine 25(9):137-140, 2005
 
P.57 掲載の参考文献
1) Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology:Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354:617-621, 1999
 
2) Hanefeld M et al:Risk factors for myocardial infarction and death in newly detected NIDDM:the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
PubMed
3) Tominaga M et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
 
4) Hanefeld M et al:Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness:the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes. Diabet Med 17:835-840, 2000
PubMed
5) Chiasson JL et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
PubMed
6) Hanefeld M et al:Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
PubMed
7) UK Prospective Diabetes Study(UKPDS)Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352:837-853, 1998
 
8) Shichiri M et al:Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 Suppl 2:B21-29, 2000
 
9) Chiasson JL et al:The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 121:928-935, 1994
PubMed
10) Coniff RF et al:A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 18:928-932, 1995
PubMed
11) Hotta N et al:The effect of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy. Diabet Med 10:355-358, 1993
PubMed
12) Kelley DE et al:Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 21:2056-2061, 1998
PubMed
13) Home PD et al:Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus:arandomized controlled trial. Diabet Med 17:762-770, 2000
 
14) Raskin P et al:Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23:583-588, 2000
PubMed
15) Anderson JH et al:Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin- analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 46:265-270, 1997
 
16) Anderson JH et al:Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 157:1249-1255, 1997
 
17) Ceriello A et al:The post-prandial state in Type 2 diabetes and endothelial dysfunction:effects of insulin aspart. Diabet Med 21:171-175, 2004
 
18) Hermanns N et al:The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 112:310-314, 2004
PubMed
19) The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group:Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
 
20) Riccardi G et al:Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus:a placebo-controlled, double-blind, multicentre study. Diabet Med 16:228-232, 1999
PubMed
21) Hollander P et al:Acarbose in the treatment of type I diabetes. Diabetes Care 20:248-253, 1997
PubMed
22) 河盛隆造ほか:糖質水解酵素阻害剤の追加療法がSU剤治療 NIDDMの血糖管理に与える影響. 糖尿病 39:527-530, 1996
 
23) 垂井清一郎ほか:αグルコシダーゼ阻害剤投与中のインスリン非依存糖尿病患者に対するAY4166併用投与による臨床的有用性の検討. 薬理と臨床 7:767-784, 1997
 
24) Schernthaner G et al:Efficacy and safety of pioglitazon versus metformin in patients with type 2 diabetes mellitus:a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068-6076, 2004
 
P.65 掲載の参考文献
1) Chiasson JL et al:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose torelance:the STOP-NIDDM triaL JAMA 290:486-494, 2003
 
2) Inoguchi T et al:High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49:1939-1945, 2000
PubMed
3) Quagliaro L et al:Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells:The role of protein kinase C and NAD(P)H oxidase activation. Diabetes 52:2795-2804, 2003
PubMed
4) Tsubouchi H et al:Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 39:444-452, 2005
PubMed
5) Etoh T et al:lncreased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia 46:1428-1437, 2003
 
6) Inoguchi T et al:Protein kinase C-dependent increase in reactive oxygen species(ROS)production in vascular tissues of diabetes:role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14(Suppl 3):S227-S232, 2003
 
7) Oliveira HR et al:Pancreatic beta-cells express phagocyte-like NAD(P)Hoxidase. Diabetes 52:1457-1463, 2003
 
8) Tsubouchi H et al:Sulfonylurea as well as elevated glucose levels stimulate reactive oxygen species production in the pancreatic beta-cell line, MIN6-a role of NAD(P)Hoxidase in beta-cells. Biochem Biophys Res Commun 326:60-65, 2005
 
9) Sonta T et al:In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker. Biochem Biophys Res Commun 330:415-422, 2005
PubMed
10) Nakayama M et al:Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an ATI receptor antagonist. Biochem Biophys Res Commun 332:927-933, 2005
 
P.75 掲載の参考文献
1) 伊藤千賀子:耐糖能異常(IGT)・境界型の自然史. 日本臨床 63 suppl 2:63-66, 2005
 
2) Knowler WC et al:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
 
3) Tuomilehto J et al:Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
PubMed
4) Pan XR et al:Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
 
5) Eriksson KF et al:Prevention of type 2(non-insulin-dependent)diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 34:891-898, 1991
PubMed
6) 葛谷英嗣ほか:日本糖尿病予防研究(Japan Diabetes Prevention Program)の経過報告. Diabetes Journal 33:126-129, 2005
 
7) Knowler WC et al:Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150-1156, 2005
PubMed
8) Li CL et al:Effect of metformin on patients with impaired glucose tolerance. Diabet Med 16:477-481, 1999
PubMed
9) Buchanan TA et al:Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51:2796-2803, 2002
PubMed
10) Chiasson JL et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
PubMed
11) Abuissa H et al:Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes:ameta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821-826, 2005
 
12) Padwal R et al:Asystematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28:736-744, 2005
PubMed
P.83 掲載の参考文献
1) Yamasaki Y et al:Asymptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery. Diabetologia 38:585-591, 1995
PubMed
2) Hanefeld M et al:Risk factors for myocardial infarction and death in newly detected NIDDM:the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
PubMed
3) DECODE study group:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999
 
4) Chiasson JL et al:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA 290:486-494, 2003
PubMed
5) Zeymer U et al:Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance:results of the randomised STOP-NIDDM trial electrocardiography substudy. Eur J Cardiovasc Prev Rehabil 11:412-415, 2004
PubMed
6) Hanefeld M et al:Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35:1073-1078, 2004
PubMed
7) Hanefeld M et al:Acarbose reduces the risk for myocardial infarction in type 2 diabeteic patients:meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
 
8) Yamasaki Y et al:Alpha-glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract 67:204-210, 2005
PubMed
9) Wright E Jr et al:Oxidative stress in the type 2 diabetes:the role of fasting and postprandial glycemia. Int J Clin Pract 60:308-314, 2006
 

V. αグルコシダーゼ阻害薬の効果的な使い方

P.90 掲載の参考文献
1) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM 1(AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
 
2) Scherer PE et al:A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995
 
3) Hu E et al:AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 120:10697-10703, 1996
 
4) Nakano Y et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120:803-812, 1996
PubMed
5) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
PubMed
6) Kubota N et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002
PubMed
7) Polonsky KS et al:Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334(12):777-783, 1996
 
8) Furukawa S et al:Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114(12):1752-1761, 2004
PubMed
9) Chiasson JL et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial. Lancet 359(9323):2072-2077, 2002
PubMed
10) Hanefeld M et al:Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:meta-analysis of seven long-term studies. Eur Heart J 25(1):10-16, 2004
PubMed
P.96 掲載の参考文献
1) Kashiwabara H et al:Insulin levels during fasting and the glucose tolerance test and Homa's index predict subsequent development of hypertension. J Hypertens 18:83-88, 2000
 
2) Goff DC Jr et al:Insulin sensitivity and the risk of incident hypertension. Insights from the Insulin Resistance Atherosclerosis Study. Diabetes Care 26:805-809, 2003
PubMed
3) Tomiyama H et al:Close relationship of abnormal glucose tolerance with endothelial dysfunction in hypertension. Hypertens 36:245-249, 2000
 
4) Knoeler WC et al:Diabetes Prevention Program Research Group:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
PubMed
5) Chiasson JL et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
PubMed
6) Chiasson JL et al:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 290:486-494, 2003
PubMed
7) Hanefeld M et al:Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
PubMed
8) Shinoda Y et al:Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance. Metabolism 55:935-939, 2006
PubMed
9) Inoue I et al:Acarbose ameliorates atherogenecity of LDL in patients with impaired glucose tolerance. Metabolism 55:946-952, 2006
 
10) Hanefeld M et al:Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35:1073-1078, 2004
PubMed
P.110 掲載の参考文献
1) Ogawa S et al:Acarbose lowers serum triglyceride and postprandial chylomicron levels in type2 diabetes. Diabetes Obes Metab 6:384-390, 2004
 
2) Simabukuro M et al:Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type2 diabetic patients:A randomized crossover study. J Clin Endocrinol Metab 91:837-842, 2006
 
3) 芳野原ほか:食後高血糖と食後高脂血症を同時に観察するテストミールのパイロットモデルの開発-テストミールAについての報告-糖尿病 49:361-371, 2006
 
4) Osonoi T et al:Effect of miglitol on plasma glucose, serum insulin and lipid metabolism in postprandial state of Type2 diabetics. Diabetes Metab 29:4S263, 2003
 
5) Yoshino G et al:The minimum dose of acarbose suppresses triglyceride concentration in remnant-like particles from fasted diabetic subjects. Horms Metab Res 28:329-330, 1996
 
6) 芳野 原ほか:二糖類分解酵素阻害剤アカルボースのNIDDM患者におけるリポ蛋白, 特にレムナント様リポ蛋白粒子中の脂質と低比重リポ蛋白粒子のサイズに与える効果について. 糖尿病 39(10):757-763, 1996
 
7) 清水弘行ほか:インスリン非依存性糖尿病症例におけるボグリボース長期投与による脂質代謝改善効果に関する検討. 臨床と研究 73:186-189, 1996
 
8) Kasama T et al:Increased cholesterol concentration in intermediate density lipoprotein fraction of normolipidemic non-insulin-dependent diabetics. Atherosclerosis 63:263-266, 1987
PubMed
9) Karpe F:Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 246:341-355, 1999
PubMed
10) Parks EJ:Recent findings in the study of postprandial lipemia. Curr Atheroscler Rep 3:462-470, 2001
 
11) Simons LA et al:Chylomicrons and chylomicron remnants in coronary artery disease;a case-control study. Atherosclerosis 65:181-189, 1987
PubMed
12) Phillips NR et al:Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 88:2762-2770, 1993
PubMed
13) Baron AD et al:The effect of short-term α-glucosidase inhibition on carbohydrate and lipid metabolism in type II (non-insulin-dependent)diabetics. Metabolism 36:409-415, 1987
 
14) Hanefeld M et al:Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14:732-737, 1991
PubMed
15) Nakajima K et al:A new assay method for the quantification of cholesterol in remnant-like particles in human serum using monoclonal anti-apo B100 and anti-apo A-1 immunoaffinity mixed gels. Clin Chim Acta 223:53-71, 1993
 
16) McNamara JR et al:Remnant-like particle(RLP)cholesterol is an independent cardiovascular disease risk factor in women:results from the Framingham Heart Study. Atherosclerosis 154:229-236, 2001
PubMed
17) Karpe F et al:HDLs and alimentary lipemia, studies in men with previous myocardial infarction at a young age. Arterioscler Thromb 13:11-22, 1993
 
18) Feingold KR et al:LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetics. Arterioscler Thromb 12:1496-1502, 1992
PubMed
19) Iwai M et al:Abnormal lipoprotein composition in normolipidemic diabetic patients. Diabetes Care 13:792-796, 1990
PubMed
20) Fernandez ML et al:Dietary fat saturation modifies the metabolism of LDL subfractions in guinea pigs. Arterioscler Thromb 13:1418-1428, 1993
 
21) McNamara JR et al:Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 12:1284-1290, 1992
PubMed
22) Kazumi T et al:Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Atherosclerosis 142:113-119, 1999
PubMed
23) Reaven GM et al:Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 92:141-146, 1993
PubMed
24) Koba S, Hirano T:Small, dense low-density lipoprotein in Japanese men with coronary artery disease. Ann Intem Med 132:762, 2000
 
25) Galeano NF et al:Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites:a potential mechanism for increased atherogenicity. J Lipid Res 39:1263-1273, 1998
PubMed
26) Hanefeld M et al:Acarbose slows progression of intima-media thickness of carotid arteries in subjects with impaired glucose tolerance. Stroke 35:1073-1078, 2004
PubMed
P.119 掲載の参考文献
1) Narayan KMV:New ADA Initiative moves beyond metabolic syndrome. Diabetes, Obesity, CVD News July, 2006, p19
 
2) Liberopoulos EN et al:Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 6(4):283-296, 2005
PubMed
3) Chiasson JL et al:STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial. JAMA 290:486-494, 2003
 
4) Ranganath L et al:Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycemic effect. Diabet Med 15:120-124, 1998
PubMed
5) Siraj ES:Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes?Cleve Clin J Med 70(8):702-704, 2003
PubMed
6) Shimabukuro M et al:Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients:a randomized cross-over study. J Clin Endocrinol Metab 91:837-842, 2006
PubMed
P.125 掲載の参考文献
1) Kawasumi M et al:Strict glycemic control ameliorates the increase of carotid IMT in patients with type 2 diabetes. Endocr J 53:45-50, 2006;
PubMed
2) 河盛隆造:ハーゲドーン賞受賞講演:糖のながれにおける肝糖取り込み率制御因子の解明. 糖尿病 49:771-774, 2006
 
3) Chiasson JL et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
PubMed
4) Chiasson JL et al for the STOP-NIDDM Trial Research Group:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA 290:486-494, 2003
 
P.131 掲載の参考文献
1) Michael MD et al:Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6:87-97, 2000
PubMed
2) Weisberg SP et al:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003
PubMed
3) Kawamori R:Asymptomatic hyperglycaemia and early atherosclerotic changes. Diabetes Res Clin Pract 40(Suppl):S35-42, 1998
 
4) Chiasson JL et al:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance, the STOP-NIDDM trial. JAMA 290:486494, 2003
 
5) Lieber CS et al:Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem Biophys Res Commun 315:699-703, 2004
PubMed
P.139 掲載の参考文献
1) 石田俊彦:日本人の糖尿病の薬物療法の特徴は?肥満と糖尿病 5:289-292, 2006
Medical*Online
2) Chiasson JL et al:The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 121:928-935, 1994
PubMed
3) Coniff RF et al:A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabete Care 18:928-932, 1995
PubMed
4) Hermanns N et al:The addition of acarbose to insulin lispro reduces acute glycaemic response in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 112:310-314, 2004
PubMed
5) Riccardi G et al:Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus:a placebo-controlled, double blind, multicenter study. Diabet Med 16:228-232, 1999
PubMed
6) Hollander P et al:Acarbose in the treatment of type 1 diabetes. Diabetes Care 20:248-253, 1997
PubMed

VI. 禁忌・慎重投与・相互作用

P.145 掲載の参考文献
1) Chiasson JL et al:Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance:facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 47:969-975, 2004
PubMed
2) 日本医薬品集 医療薬2006年版, 日本医薬品集フォーラム, じほう, 2006
 
3) Morseth SL et al:AO-128のラットにおける繁殖試験. 薬理と治療 19:4325-4340, 199
 
4) 大野友彦:α-グルコシダーゼ阻害薬による消化器系副作用, 特に腸閉塞発症についての検討. 新薬と臨床 44:1114-1116, 1995
 
5) 戸田剛太郎ほか:アカルボース投与例に発生した肝障害の臨床的特徴に関する検討. 臨床医薬 16:1047-1054, 2000
Medical*Online
6) 神代龍吉:薬物性肝障害をめぐって, 各治療薬と薬物性肝障害 糖尿病治療薬と薬物性肝障害. 医学のあゆみ 214:799-803, 2005
 
7) 大野敦ほか:糖尿病透析患者においてインスリンからacarbose(グルコバイ)への切り替えは可能か 長期フォロー例での検討. 神奈川医学会雑誌 23:184-191, 1996
 

VII. 副作用と服薬指導の注意点

P.152 掲載の参考文献
1) Chiasson JL et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002
PubMed
2) 松本直樹ほか:α-glucosidase阻害作用による腸管内発酵反応-糞便中短鎖脂肪酸排泄量と呼気中水素濃度に関する検討-. 消化と吸収 24:15-18, 2001
 
3) 後藤由夫:ミグリトールの2型糖尿病に対する臨床効果第II相・用量反応性試験. 薬理と治療 33:1099-1111, 2005
 
4) 大井一弥ほか:アカルボースによる放屁増加の副作用モニタリング. 医療薬学 29:375-378, 2003
Medical*Online
5) May C:Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes(NIDDM), treated with sulphonylureas. Diabetes und Stoffwechsel 4:3-8, 1995
 

VIII. αグルコシダーゼ阻害薬の今後の展望

P.157 掲載の参考文献
1) Yamagishi S et al:Diabetic vascular complications:Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279-2299, 2005
PubMed
2) DECODE Study Group:Glucose tolerance and cardiovascular mortality:Comparison of fasting and 2-hour diagnostic criteria. Arch Intem Med 161:397-405, 2001
 
3) Tominaga M et al:lmpaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose:the Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
 
4) Hanefeld M et al:Risk factors for myocardial infarction and death in newly detected NIDDM:The diabetes intervention study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
PubMed
5) Ceriello A:Hyperglycaemia:the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 12:42-46, 1999
 
6) Chiasson JL et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002
PubMed
7) Chiasson JL et al:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 290:486-494, 2003
PubMed
8) Hanefeld M et al:Acarbose reduces the risk of myocardial infarction in type 2 diabetic patient:meta-analysis of seven long-term studies. Eur Heart J 25:1016, 2004
 

IX. 食後血糖に関する疫学研究

P.165 掲載の参考文献
1) Hanefeld M et al:Risk factors for myocardial infarction and death in newly detected NIDDM:the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
PubMed
2) Benfante RJ et al:Risk factors in middle age that predict early and late onset of coronary heart disease. J Clin Epidemiol 42:95-104, 1989
PubMed
3) The DECODE study group:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999
 
4) The DECODE study group:Glucose tolerance and cardiovascular mortality:comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405, 2001
 
5) Shaw JE et al:Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42:1050-1054, 1999
PubMed
6) Tominaga M et al:lmpaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Tha Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
 
7) Balkau B et al:High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21:360-367, 1998
 
8) DECODA Study Group:Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 47:385-394, 2004
 
9) Ceriello A:The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 46(Suppl 1):M9-16, 2003
 
10) Ceriello A:Impaired glucose tolerance and cardiovascular disease:the possible role of post-prandial hyperglycemia. Am Heart J 147:803-807, 2004
PubMed
11) Shaw JE et al:Impaired fasting glucose or impaired glucose tolerance:what best predicts future diabetes in Mauritius? Diabetes Care 22:399-402, 1999
 
12) de Vegt F et al:Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population:The Hoorn Study. JAMA 285:2109-2113, 2001
 
13) Pan XR et al:Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
 
14) Tuomilehto J et al:Prevention of type2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
 
15) Knowler WC et al:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med 346:393-403, 2002
 
16) Dyson PA et al:The Fasting Hyperglycaemia Study:II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism 46(Suppl 1):50-55, 1997
PubMed
17) Chiasson JL et al:STOP-NIDDM Trial Research Group:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial. JAMA 290:486-494, 2003
 
18) Ceriello A et al:Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycaemia on endothelial dysfunction and oxidative stress generation. Circulation 106:1211-1218, 2002
PubMed

書評

最近チェックした商品履歴

Loading...